{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:06Z","timestamp":1793608146136,"version":"4.5.0"},"posted":{"date-parts":[[2026,6,3]]},"group-title":"In Review","reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,13]]},"abstract":"<title>Abstract<\/title>\n                <p>Dual antiretroviral therapy with dolutegravir and lamivudine (DTG\/3TC) is a recommended first-line regimen for people with HIV, but whether reduced-drug therapy maintains adequate antiviral pressure within lymph node (LN) reservoirs remains uncertain.  In the DUALITY clinical trial, peripheral HIV-1 reservoir markers declined similarly in participants initiating DTG\/3TC or dolutegravir-based triple therapy. Here we investigated viral persistence and antiretroviral drug distribution in LN using multimodal imaging. In 39 participants undergoing inguinal LN excision at baseline or during the first year of treatment, HIV-1 DNA and RNA were detected by DNAscope\/RNAscope and antiretroviral spatial distribution was mapped by mass spectrometry imaging. HIV-1\u2013infected cells declined rapidly after treatment initiation, with comparable reductions between treatment groups. Antiretrovirals were widely detected within LN tissue regions susceptible to containing HIV-positive cells. These findings provide spatial evidence that DTG\/3TC achieves effective LN penetration and supports effective antiviral exposure within a key anatomical HIV reservoir.<\/p>","DOI":"10.21203\/rs.3.rs-9402443\/v1","type":"posted-content","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:24:44Z","timestamp":1780482284000},"source":"Crossref","is-referenced-by-count":0,"title":["First-line dolutegravir\/lamivudine penetrates lymph nodes and reduces HIV reservoirs comparably to triple therapy"],"prefix":"10.21203","author":[{"given":"Jose","family":"Molto","sequence":"first","affiliation":[{"name":"Fight Against Infections, Infectious Diseases Department, Hospital Germans Trias i Pujol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Rosen","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Bondoc","sequence":"additional","affiliation":[{"name":"Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Blay","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Caballero","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Garcia-Guerrero","sequence":"additional","affiliation":[{"name":"IrsiCaixa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6750-2318","authenticated-orcid":false,"given":"Maria","family":"Puertas","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-8849","authenticated-orcid":false,"given":"Igor","family":"Moraes-Cardoso","sequence":"additional","affiliation":[{"name":"IrsiCaixa, Badalona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita contra les Infeccions, Badalona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-0217","authenticated-orcid":false,"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[{"name":"IrsiCaixa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-407X","authenticated-orcid":false,"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[{"name":"IrsiCaixa, Hospital Universitari Germans Trias I Pujol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Kashuba","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Estes","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-2129","authenticated-orcid":false,"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"IrsiCaixa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review","volume":"10","author":"Patel R","year":"2021","unstructured":"Patel R et al (2021) HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infect Dis Ther 10:2051\u20132070","journal-title":"Infect Dis Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection","volume":"36","author":"Cahn P","year":"2022","unstructured":"Cahn P et al (2022) Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS 36:39\u201348","journal-title":"AIDS"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1093\/jac\/dkaf345","article-title":"Effectiveness of first-line lamivudine\/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort","volume":"80","author":"Vergori A","year":"2025","unstructured":"Vergori A et al (2025) Effectiveness of first-line lamivudine\/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort. J Antimicrob Chemother 80:3082\u20133091","journal-title":"J Antimicrob Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70120","article-title":"Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025","author":"Ambrosioni J","year":"2025","unstructured":"Ambrosioni J et al (2025) Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. HIV Med. https:\/\/doi.org\/10.1111\/hiv.70120","journal-title":"HIV Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/jiae530","article-title":"Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood","volume":"231","author":"Bail\u00f3n L","year":"2025","unstructured":"Bail\u00f3n L et al (2025) Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. J Infect Dis 231:600\u2013610","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cpt.2186","article-title":"The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy","volume":"109","author":"Scholz EMB","year":"2021","unstructured":"Scholz EMB, Kashuba ADM (2021) The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy. Clin Pharmacol Ther 109:918\u2013927","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.chom.2023.08.020","article-title":"Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART","volume":"31","author":"Banga R","year":"2023","unstructured":"Banga R et al (2023) Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART. Cell Host Microbe 31:1714\u20131731e9","journal-title":"Cell Host Microbe"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/cpt.1883","article-title":"The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons","volume":"108","author":"Fletcher CV","year":"2020","unstructured":"Fletcher CV et al (2020) The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons. Clin Pharmacol Ther 108:971\u2013975","journal-title":"Clin Pharmacol Ther"},{"key":"ref9","first-page":"e00019","article-title":"Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates","volume":"65","author":"Scholz EMB","year":"2021","unstructured":"Scholz EMB et al (2021) Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates. Antimicrob Agents Chemother 65:e00019\u201321","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1570162X20666211227161237","article-title":"The Importance of Tissue Sanctuaries and Cellular Reservoirs of HIV-1","volume":"20","author":"Kalada W","year":"2022","unstructured":"Kalada W, Cory TJ (2022) The Importance of Tissue Sanctuaries and Cellular Reservoirs of HIV-1. Curr HIV Res 20:102\u2013110","journal-title":"Curr HIV Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e25895","DOI":"10.1002\/jia2.25895","article-title":"Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent","volume":"25","author":"Rosen EP","year":"2022","unstructured":"Rosen EP et al (2022) Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent. J Int AIDS Soc 25:e25895","journal-title":"J Int AIDS Soc"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher CV","year":"2014","unstructured":"Fletcher CV et al (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111:2307\u20132312","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/QAD.0000000000003201","article-title":"Persistent HIV Transcription and Variable ARV Penetration in Lymph Nodes During Plasma Viral Suppression","volume":"36","author":"Fletcher CV","year":"2022","unstructured":"Fletcher CV et al (2022) Persistent HIV Transcription and Variable ARV Penetration in Lymph Nodes During Plasma Viral Suppression. AIDS 36:985\u2013990","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1128\/AAC.04952-14","article-title":"Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs","volume":"59","author":"Thompson CG","year":"2015","unstructured":"Thompson CG et al (2015) Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob Agents Chemother 59:2944\u20132948","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.20411\/pai.v1i1.100","article-title":"Defining HIV and SIV Reservoirs in Lymphoid Tissues","volume":"1","author":"Deleage C","year":"2016","unstructured":"Deleage C et al (2016) Defining HIV and SIV Reservoirs in Lymphoid Tissues. Pathog Immun 1:68\u2013106","journal-title":"Pathog Immun"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e0060922","DOI":"10.1128\/aac.00609-22","article-title":"Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates","volume":"66","author":"Devanathan AS","year":"2022","unstructured":"Devanathan AS et al (2022) Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates. Antimicrob Agents Chemother 66:e0060922","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3851\/IMP3236","article-title":"Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women","volume":"23","author":"Weber MD","year":"2018","unstructured":"Weber MD et al (2018) Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women. Antivir Ther 23:495\u2013504","journal-title":"Antivir Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.119.259150","article-title":"Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans","volume":"370","author":"Burgunder E","year":"2019","unstructured":"Burgunder E et al (2019) Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans. J Pharmacol Exp Ther 370:360\u2013368","journal-title":"J Pharmacol Exp Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.48.1.176-182.2004","article-title":"Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily","volume":"48","author":"Yuen GJ","year":"2004","unstructured":"Yuen GJ et al (2004) Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 48:176\u2013182","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults","volume":"25","author":"Min S","year":"2011","unstructured":"Min S et al (2011) Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 25:1737\u20131745","journal-title":"AIDS"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"Min S","year":"2010","unstructured":"Min S et al (2010) Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54:254\u2013258","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","author":"Thurman AR","year":"2021","unstructured":"Thurman AR et al (2021) Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. EClinicalMedicine 36, 100893"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00216-014-8220-y","article-title":"Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization","volume":"407","author":"Bokhart MT","year":"2015","unstructured":"Bokhart MT et al (2015) Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization. Anal Bioanal Chem 407:2073\u20132084","journal-title":"Anal Bioanal Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1128\/AAC.01148-15","article-title":"Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells","volume":"59","author":"Dumond JB","year":"2015","unstructured":"Dumond JB et al (2015) Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother 59:6395\u20136401","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/323995","article-title":"Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates","volume":"184","author":"Duan C","year":"2001","unstructured":"Duan C et al (2001) Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. J Infect Dis 184:1336\u20131340","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jac\/dkae147","article-title":"Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing","volume":"79","author":"Else LJ","year":"2024","unstructured":"Else LJ et al (2024) Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing. J Antimicrob Chemother 79:1597\u20131605","journal-title":"J Antimicrob Chemother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/pharmaceutics14061285","article-title":"Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue","volume":"14","author":"Else L","year":"2022","unstructured":"Else L et al (2022) Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue. Pharmaceutics 14:1285","journal-title":"Pharmaceutics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell ML","year":"2013","unstructured":"Cottrell ML, Hadzic T, Kashuba ADM (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52:981\u2013994","journal-title":"Clin Pharmacokinet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e1013466","DOI":"10.1371\/journal.ppat.1013466","article-title":"Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy","volume":"21","author":"Puertas MC","year":"2025","unstructured":"Puertas MC et al (2025) Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy. PLoS Pathog 21:e1013466","journal-title":"PLoS Pathog"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1742-4690-10-41","article-title":"Cell-associated HIV RNA: a dynamic biomarker of viral persistence","volume":"10","author":"Pasternak AO","year":"2013","unstructured":"Pasternak AO, Lukashov VV, Berkhout B (2013) Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10:41","journal-title":"Retrovirology"},{"key":"ref31","author":"Scherpenisse M","year":"2021","unstructured":"Scherpenisse M, Kootstra NA, Bakker M, Berkhout B, Pasternak AO (2021) Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy. mBio 12, e00099-21"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e02064","DOI":"10.1128\/JVI.02064-20","article-title":"Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption","volume":"95","author":"Ziani W","year":"2021","unstructured":"Ziani W et al (2021) Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption. J Virol 95:e02064\u2013e02020","journal-title":"J Virol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.30.673277","author":"King IV","year":"2025","unstructured":"King IV et al (2025) Origin and Correlates of Viral Rebound in SIV-Infected Rhesus Macaques Following ART Discontinuation. bioRxiv 2025.08.30.673277 10.1101\/2025.08.30.673277"},{"key":"ref34","unstructured":"Emtriva Prescribing Information https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emtriva-epar-product-information_en.pdf"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi M","year":"2011","unstructured":"Kobayashi M et al (2011) In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55:813\u2013821","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.coviro.2016.07.002","article-title":"Imaging lymphoid tissues in nonhuman primates to understand SIV pathogenesis and persistence","volume":"19","author":"Deleage C","year":"2016","unstructured":"Deleage C, Turkbey B, Estes JD (2016) Imaging lymphoid tissues in nonhuman primates to understand SIV pathogenesis and persistence. Curr Opin Virol 19:77\u201384","journal-title":"Curr Opin Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.smim.2008.06.001","article-title":"The lymph node in HIV pathogenesis","volume":"20","author":"Lederman MM","year":"2008","unstructured":"Lederman MM, Margolis L (2008) The lymph node in HIV pathogenesis. Semin Immunol 20:187\u2013195","journal-title":"Semin Immunol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9402443\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9402443\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:06:11Z","timestamp":1793606771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9402443\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":37,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9402443\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41467-026-78190-9","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,6,3]]},"subtype":"preprint"}}